{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,5]],"date-time":"2026-10-05T16:12:06Z","timestamp":1791216726785,"version":"4.1.0"},"reference-count":53,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2024,10,1]],"date-time":"2024-10-01T00:00:00Z","timestamp":1727740800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2024,10,1]],"date-time":"2024-10-01T00:00:00Z","timestamp":1727740800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2024,6,19]],"date-time":"2024-06-19T00:00:00Z","timestamp":1718755200000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":["clinicalkey.fr","clinicalkey.jp","clinicalkey.com.au","clinicalkey.es","clinicalkey.com","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Seminars in Arthritis and Rheumatism"],"published-print":{"date-parts":[[2024,10]]},"DOI":"10.1016\/j.semarthrit.2024.152471","type":"journal-article","created":{"date-parts":[[2024,6,22]],"date-time":"2024-06-22T15:27:17Z","timestamp":1719070037000},"page":"152471","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":10,"special_numbering":"C","title":["Role of intravenous immunoglobulins in systemic sclerosis (SSc): A systematic literature review"],"prefix":"10.1016","volume":"68","author":[{"ORCID":"https:\/\/orcid.org\/0009-0000-8230-7476","authenticated-orcid":false,"given":"Sasza","family":"Koczanowski","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kathleen","family":"Morrisroe","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jessica","family":"Fairley","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mandana","family":"Nikpour","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Shereen","family":"Oon","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Zoe","family":"Brown","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"issue":"10","key":"10.1016\/j.semarthrit.2024.152471_bib0001","doi-asserted-by":"crossref","first-page":"e267","DOI":"10.1016\/j.lpm.2014.08.001","article-title":"Pathophysiology of systemic sclerosis: state of the art in 2014","volume":"43","author":"Dumoitier","year":"2014","journal-title":"La Presse M\u00e9dicale"},{"issue":"11","key":"10.1016\/j.semarthrit.2024.152471_bib0002","doi-asserted-by":"crossref","first-page":"1203","DOI":"10.1080\/17512433.2020.1832466","article-title":"Current immunosuppressive and antifibrotic therapies of systemic sclerosis and emerging therapeutic strategies","volume":"13","author":"Fallet","year":"2020","journal-title":"Expert Rev Clin Pharmacol"},{"issue":"suppl_5","key":"10.1016\/j.semarthrit.2024.152471_bib0003","doi-asserted-by":"crossref","first-page":"v44","DOI":"10.1093\/rheumatology\/ken309","article-title":"Skin involvement in systemic sclerosis","volume":"47","author":"Czirjak","year":"2008","journal-title":"Rheumatology"},{"issue":"c90, 100883537","key":"10.1016\/j.semarthrit.2024.152471_bib0004","doi-asserted-by":"crossref","first-page":"25","DOI":"10.1016\/j.clim.2018.12.006","article-title":"Intravenous immunoglobulin (IVIG) in the vanguard therapy of systemic sclerosis","volume":"199","author":"Gomes","year":"2019","journal-title":"Clin Immunol"},{"issue":"2 Suppl 76","key":"10.1016\/j.semarthrit.2024.152471_bib0005","first-page":"166","article-title":"Treatment of early diffuse systemic sclerosis skin disease","volume":"31","author":"Frech","year":"2013","journal-title":"Clin Exp Rheumatol"},{"key":"10.1016\/j.semarthrit.2024.152471_bib0006","doi-asserted-by":"crossref","first-page":"326","DOI":"10.1007\/s12026-014-8615-z","article-title":"Intravenous immunoglobulins (IVIG) in systemic sclerosis: a challenging yet promising future","volume":"61","author":"Cantarini","year":"2015","journal-title":"Immunol Res"},{"issue":"4","key":"10.1016\/j.semarthrit.2024.152471_bib0007","doi-asserted-by":"crossref","first-page":"377","DOI":"10.1016\/j.autrev.2017.02.008","article-title":"Intravenous immunoglobulins in systemic sclerosis: data from a French nationwide cohort of 46 patients and review of the literature","volume":"16","author":"Sanges","year":"2017","journal-title":"Autoimmun Rev"},{"key":"10.1016\/j.semarthrit.2024.152471_bib0008","doi-asserted-by":"crossref","first-page":"201","DOI":"10.1007\/s12016-009-8155-9","article-title":"Evidence for the use of intravenous immunoglobulins\u2014A review of the literature","volume":"38","author":"Kivity","year":"2010","journal-title":"Clin Rev Allergy Immunol"},{"issue":"3","key":"10.1016\/j.semarthrit.2024.152471_bib0009","doi-asserted-by":"crossref","first-page":"277","DOI":"10.1136\/ard.61.3.277-a","article-title":"Home sequential high dose intravenous immunoglobulins in systemic autoimmune disease","volume":"61","author":"Hachulla","year":"2002","journal-title":"Ann Rheum Dis"},{"issue":"4","key":"10.1016\/j.semarthrit.2024.152471_bib0010","doi-asserted-by":"crossref","first-page":"257","DOI":"10.1016\/j.autrev.2006.08.011","article-title":"Safety of intravenous immunoglobulin (IVIG) therapy","volume":"6","author":"Katz","year":"2007","journal-title":"Autoimmun Rev"},{"key":"10.1016\/j.semarthrit.2024.152471_bib0011","doi-asserted-by":"crossref","first-page":"207","DOI":"10.1007\/s100670050158","article-title":"Skin score decrease in systemic sclerosis patients treated with intravenous immunoglobulin\u2013a preliminary report","volume":"19","author":"Levy","year":"2000","journal-title":"Clin Rheumatol"},{"issue":"SUPPL. 3","key":"10.1016\/j.semarthrit.2024.152471_bib0012","article-title":"A randomized, double-blind trial of intravenous immunoglobulin in diffuse cutaneous systemic scleros","volume":"71","author":"Takehara","year":"2013","journal-title":"Ann Rheumatic Dis"},{"key":"10.1016\/j.semarthrit.2024.152471_bib0013","doi-asserted-by":"crossref","first-page":"347","DOI":"10.1007\/s10067-008-1062-2","article-title":"Combined plasmapheresis and high-dose intravenous immunoglobulin treatment in systemic sclerosis for 12 months: follow-up of immunopathological and clinical effects","volume":"28","author":"Szekanecz","year":"2009","journal-title":"Clin Rheumatol"},{"issue":"2","key":"10.1016\/j.semarthrit.2024.152471_bib0014","doi-asserted-by":"crossref","first-page":"236","DOI":"10.3899\/jrheum.140833","article-title":"Intravenous immunoglobulin may be an effective therapy for refractory, active diffuse cutaneous systemic sclerosis","volume":"42","author":"Poelman","year":"2015","journal-title":"J Rheumatol"},{"issue":"Supplement 1","key":"10.1016\/j.semarthrit.2024.152471_bib0015","first-page":"206","article-title":"Corticosteroid-sparing benefit of intravenous immunoglobulins in systemic sclerosis-associated myopathy: a retrospective study of 52 patients","volume":"3","author":"Chaigne","year":"2018","journal-title":"J Scleroderma Relat Disord"},{"issue":"3","key":"10.1016\/j.semarthrit.2024.152471_bib0016","doi-asserted-by":"crossref","first-page":"1005","DOI":"10.1002\/art.20195","article-title":"Intravenous immunoglobulin modulates cutaneous involvement and reduces skin fibrosis in systemic sclerosis: an open-label study","volume":"50","author":"Levy","year":"2004","journal-title":"Arthritis Rheum"},{"issue":"Supplement 1","key":"10.1016\/j.semarthrit.2024.152471_bib0017","first-page":"i161","article-title":"An observational study of intravenous immunoglobulin therapy in the treatment of gastrointestinal involvement in systemic sclerosis","volume":"54","author":"Raja","year":"2015","journal-title":"Rheumatology"},{"issue":"Supplement 2","key":"10.1016\/j.semarthrit.2024.152471_bib0018","first-page":"856","article-title":"Use of intravenous immunoglobulin therapy in patients with systemic sclerosis: a spanish multicenter experience","volume":"78","author":"Jaime","year":"2019","journal-title":"Ann Rheum Dis"},{"issue":"7","key":"10.1016\/j.semarthrit.2024.152471_bib0019","doi-asserted-by":"crossref","first-page":"977","DOI":"10.1136\/ard.2006.060111","article-title":"Intravenous immunoglobulins improve the function and ameliorate joint involvement in systemic sclerosis: a pilot study","volume":"66","author":"Nacci","year":"2007","journal-title":"Ann Rheum Dis"},{"issue":"12","key":"10.1016\/j.semarthrit.2024.152471_bib0020","doi-asserted-by":"crossref","DOI":"10.1016\/j.autrev.2021.102981","article-title":"Intravenous immunoglobulins reduce skin thickness in systemic sclerosis: evidence from Systematic Literature Review and from real life experience","volume":"20","author":"Agostini","year":"2021","journal-title":"Autoimmun Rev"},{"issue":"19\u201320","key":"10.1016\/j.semarthrit.2024.152471_bib0021","doi-asserted-by":"crossref","first-page":"1070","DOI":"10.1007\/s00508-020-01669-y","article-title":"Low dose intravenous immunoglobulin in addition to cyclophosphamide in systemic sclerosis: single centre experience","volume":"133","author":"Perkovic","year":"2021","journal-title":"Wien Klin Wochenschr"},{"issue":"5","key":"10.1016\/j.semarthrit.2024.152471_bib0022","doi-asserted-by":"crossref","first-page":"1058","DOI":"10.1111\/j.1365-2133.2007.07777.x","article-title":"High-dose intravenous immunoglobulin infusion as treatment for diffuse scleroderma","volume":"156","author":"Ihn","year":"2007","journal-title":"Br J Dermatol"},{"issue":"2","key":"10.1016\/j.semarthrit.2024.152471_bib0023","doi-asserted-by":"crossref","first-page":"170","DOI":"10.3109\/03009742.2013.868510","article-title":"Improvement in lung fibrosis using intravenous immunoglobulin in systemic sclerosis with myositis","volume":"43","author":"Mauhin","year":"2014","journal-title":"Scand J Rheumatol"},{"key":"10.1016\/j.semarthrit.2024.152471_bib0024","author":"Matsuda","year":"2024","journal-title":"J Dermatol"},{"issue":"11","key":"10.1016\/j.semarthrit.2024.152471_bib0025","doi-asserted-by":"crossref","DOI":"10.1016\/j.autrev.2023.103441","article-title":"Immunoglobulins in systemic sclerosis management. A large multicenter experience","volume":"22","author":"Tandaipan","year":"2023","journal-title":"Autoimmun Rev"},{"key":"10.1016\/j.semarthrit.2024.152471_bib0026","unstructured":"Hoogen F., Khanna D., Fransen J., et al. 2013 classification criteria for systemic sclerosis: an American College of Rheumatology\/European league against Rheumatism collaborative initiative. 2013."},{"key":"10.1016\/j.semarthrit.2024.152471_bib0027","series-title":"Cochrane handbook for systematic reviews of interventions","first-page":"205","article-title":"Assessing risk of bias in a randomized trial","author":"Higgins","year":"2019"},{"key":"10.1016\/j.semarthrit.2024.152471_bib0028","first-page":"355","article-title":"ROBINS-I: a tool for assessing risk of bias in non-randomised studies of interventions","author":"Sterne","year":"2016","journal-title":"BMJ"},{"issue":"1","key":"10.1016\/j.semarthrit.2024.152471_bib0029","doi-asserted-by":"crossref","first-page":"75","DOI":"10.1136\/ard.40.1.75","article-title":"An articular index for the assessment of osteoarthritis","volume":"40","author":"Doyle","year":"1981","journal-title":"Ann Rheum Dis"},{"issue":"2","key":"10.1016\/j.semarthrit.2024.152471_bib0030","doi-asserted-by":"crossref","first-page":"165","DOI":"10.1097\/MRR.0b013e3282fc0f93","article-title":"Reliability and validity of the visual analogue scale for disability in patients with chronic musculoskeletal pain","volume":"31","author":"Boonstra","year":"2008","journal-title":"Internat J Rehabilit Res"},{"issue":"1","key":"10.1016\/j.semarthrit.2024.152471_bib0031","doi-asserted-by":"crossref","first-page":"99","DOI":"10.3233\/JND-180358","article-title":"Responsiveness to change of 5-point MRC scale, endurance and functional evaluation for assessing myositis in daily clinical practice","volume":"6","author":"Landon-Cardinal","year":"2019","journal-title":"J Neuromuscul Dis"},{"issue":"8","key":"10.1016\/j.semarthrit.2024.152471_bib0032","doi-asserted-by":"crossref","first-page":"1385","DOI":"10.1002\/acr.21964","article-title":"Significance of palpable tendon friction rubs in early diffuse cutaneous systemic sclerosis","volume":"65","author":"Dor\u00e9","year":"2013","journal-title":"Arthritis Care Res"},{"key":"10.1016\/j.semarthrit.2024.152471_bib0033","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1186\/1477-7525-6-31","article-title":"The Reflux Disease Questionnaire: a measure for assessment of treatment response in clinical trials","volume":"6","author":"Shaw","year":"2008","journal-title":"Health Qual Life Outcomes"},{"issue":"1","key":"10.1016\/j.semarthrit.2024.152471_bib0034","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1186\/s13075-021-02506-x","article-title":"Performance of the UCLA scleroderma clinical trials consortium gastrointestinal tract 2.0 instrument as a clinical decision aid in the routine clinical care of patients with systemic sclerosis","volume":"23","author":"Zampatti","year":"2021","journal-title":"Arthritis Res Ther"},{"issue":"5 Suppl 39","key":"10.1016\/j.semarthrit.2024.152471_bib0035","first-page":"S14","article-title":"The health assessment questionnaire (HAQ)","volume":"23","author":"Bruce","year":"2005","journal-title":"Clin Exp Rheumatol"},{"issue":"1","key":"10.1016\/j.semarthrit.2024.152471_bib0036","doi-asserted-by":"crossref","first-page":"23","DOI":"10.1186\/s13075-019-1809-y","article-title":"Minimal clinically important differences for the modified rodnan skin score: results from the scleroderma lung studies (SLS-I and SLS-II)","volume":"21","author":"Khanna","year":"2019","journal-title":"Arthritis Res Ther"},{"key":"10.1016\/j.semarthrit.2024.152471_bib0037","doi-asserted-by":"crossref","unstructured":"Denton C.P. Challenges in systemic sclerosis trial design. Semin Arthritis Rheum. Dec 2019;49(3S):S3\u2013S7. doi:10.1016\/j.semarthrit.2019.09.019.","DOI":"10.1016\/j.semarthrit.2019.09.019"},{"key":"10.1016\/j.semarthrit.2024.152471_bib0038","doi-asserted-by":"crossref","first-page":"801","DOI":"10.1007\/s10067-012-1940-5","article-title":"Intravenous immunoglobulin therapy in adult patients with polymyositis\/dermatomyositis: a systematic literature review","volume":"31","author":"Wang","year":"2012","journal-title":"Clin Rheumatol"},{"issue":"2","key":"10.1016\/j.semarthrit.2024.152471_bib0039","doi-asserted-by":"crossref","first-page":"124","DOI":"10.1016\/j.autrev.2009.04.003","article-title":"Intravenous immunoglobulin as add on treatment with mycophenolate mofetil in severe myositis","volume":"9","author":"Danieli","year":"2009","journal-title":"Autoimmun Rev"},{"issue":"4","key":"10.1016\/j.semarthrit.2024.152471_bib0040","first-page":"214","article-title":"Successful treatment of a refractory dysbiotic intestinal pseudo-obstruction in a patient with systemic sclerosis-polymyositis overlap syndrome by intravenous immunoglobulin administration possibly related to gut flora normalisation","volume":"35","author":"Kamei","year":"2017","journal-title":"Clin Exp Rheumatol"},{"issue":"91","key":"10.1016\/j.semarthrit.2024.152471_bib0041","first-page":"S168","article-title":"Case report Intravenous immunoglobulin therapy for severe gastrointestinal involvement in systemic sclerosis","volume":"33","author":"Clark","year":"2015","journal-title":"Clin Exp Rheumatol"},{"issue":"11","key":"10.1016\/j.semarthrit.2024.152471_bib0042","doi-asserted-by":"crossref","first-page":"G1052","DOI":"10.1152\/ajpgi.00034.2016","article-title":"Role of muscarinic-3 receptor antibody in systemic sclerosis: correlation with disease duration and effects of IVIG","volume":"310","author":"Kumar","year":"2016","journal-title":"Am J Physiol-Gastrointest Liver Physiol"},{"issue":"1","key":"10.1016\/j.semarthrit.2024.152471_bib0043","first-page":"126","article-title":"Steroid-induced diabetes in rheumatologic patients","volume":"32","author":"Angelopoulos","year":"2014","journal-title":"Clin Exp Rheumatol"},{"issue":"4","key":"10.1016\/j.semarthrit.2024.152471_bib0044","doi-asserted-by":"crossref","first-page":"631","DOI":"10.1016\/j.rdc.2006.07.002","article-title":"Epidemiology of osteoporosis in rheumatic diseases","volume":"32","author":"Sinigaglia","year":"2006","journal-title":"Rheumatic Dis Clinics"},{"issue":"1","key":"10.1016\/j.semarthrit.2024.152471_bib0045","doi-asserted-by":"crossref","first-page":"181","DOI":"10.3899\/jrheum.100692","article-title":"Reactivation of hepatitis B virus after steroid treatment in rheumatic diseases","volume":"38","author":"Cheng","year":"2011","journal-title":"J Rheumatol"},{"key":"10.1016\/j.semarthrit.2024.152471_bib0046","article-title":"Effects of nintedanib in patients with limited cutaneous systemic sclerosis and interstitial lung disease","author":"Allanore","year":"2023","journal-title":"Rheumatology (Oxford)"},{"issue":"12","key":"10.1016\/j.semarthrit.2024.152471_bib0047","doi-asserted-by":"crossref","DOI":"10.1016\/j.autrev.2021.102978","article-title":"Pharmacological treatments for SSc-ILD: systematic review and critical appraisal of the evidence","volume":"20","author":"Vonk","year":"2021","journal-title":"Autoimmun Rev"},{"key":"10.1016\/j.semarthrit.2024.152471_bib0048","series-title":"D101 case REPORTS: interstitial lung disease and diffuse alveolar hemorrhage","first-page":"A5789","article-title":"Interstitial lung disease (ILD) Responsive To Rituximab and not standard immunosuppression-A case presentation","author":"Naqvi","year":"2013"},{"issue":"3","key":"10.1016\/j.semarthrit.2024.152471_bib0049","doi-asserted-by":"crossref","first-page":"674","DOI":"10.1212\/WNL.47.3.674","article-title":"Complications of intravenous immune globulin treatment in neurologic disease","volume":"47","author":"Brannagan","year":"1996","journal-title":"Neurology"},{"key":"10.1016\/j.semarthrit.2024.152471_bib0050","doi-asserted-by":"crossref","first-page":"818","DOI":"10.1007\/s00415-003-1085-1","article-title":"Side effects of intravenous immunoglobulins in neurological autoimmune disorders: a prospective study","volume":"250","author":"Stangel","year":"2003","journal-title":"J Neurol"},{"issue":"6","key":"10.1016\/j.semarthrit.2024.152471_bib0051","doi-asserted-by":"crossref","first-page":"668","DOI":"10.1007\/s12026-018-9047-y","article-title":"Intravenous immunoglobulins for rheumatic disorders and thromboembolic events-a case series and review of the literature","volume":"66","author":"Lidar","year":"2018","journal-title":"Immunol Res"},{"issue":"9","key":"10.1016\/j.semarthrit.2024.152471_bib0052","first-page":"1149","article-title":"The challenge of an increasingly expensive blood system","volume":"168","author":"Wilson","year":"2003","journal-title":"Cmaj"},{"issue":"4","key":"10.1016\/j.semarthrit.2024.152471_bib0053","doi-asserted-by":"crossref","first-page":"705","DOI":"10.1016\/j.rdc.2020.07.009","article-title":"Racial disparities in systemic sclerosis","volume":"46","author":"Moore","year":"2020","journal-title":"Rheumatic Dis Clin"}],"container-title":["Seminars in Arthritis and Rheumatism"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0049017224001112?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0049017224001112?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2024,10,7]],"date-time":"2024-10-07T08:56:02Z","timestamp":1728291362000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0049017224001112"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2024,10]]},"references-count":53,"alternative-id":["S0049017224001112"],"URL":"https:\/\/doi.org\/10.1016\/j.semarthrit.2024.152471","relation":{},"ISSN":["0049-0172"],"issn-type":[{"value":"0049-0172","type":"print"}],"subject":[],"published":{"date-parts":[[2024,10]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Role of intravenous immunoglobulins in systemic sclerosis (SSc): A systematic literature review","name":"articletitle","label":"Article Title"},{"value":"Seminars in Arthritis and Rheumatism","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.semarthrit.2024.152471","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2024 The Author(s). Published by Elsevier Inc.","name":"copyright","label":"Copyright"}],"article-number":"152471"}}